Contact Us
Schwab Client Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about Delix Therapeutics

Recent news which mentions Delix Therapeutics

Psilocybin Drug By Psilera Could Treat Frontotemporal Dementia Without Psychoactive Effects
Tickers NEWS
Tags Health Care Benzinga Psychedelic Research
From Benzinga
Delix's Non-Hallucinogen Completes Safe Administration To First Clinical Trial Cohort
Tags Markets Psychedelics Market News
From Benzinga
Delix's Non-Hallucinogenic Psychoplastogen Enters Phase 1 Trial
Tags Psychoplastogens Benzinga Delix Therapeutics
From Benzinga
Delix: Elucidating How Psychedelics Actually Induce Neuroplasticity Vs. SSRIs
Tags Cannabis News Market News
From Benzinga
Delix Inks Deal With Cellectricon; Psyched Wellness Partners With Spacestation
Tickers PSYCF
Tags Management Contracts Global
From Benzinga
Psychedelics Companies Share Corporate Updates: Numinus, Delix, Tryp And Small Pharma
Tickers DMTTF NUMIF TRYPF
Tags News Cannabis Market News
From Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
Tickers ATAI AWKNF CYBN FTRP
Tags Markets Small Cap ATAI
From Benzinga
Delix Therapeutics Raises $30M In Convertible Note Financing, Will Enhance Drug Development Program
Tags General psychedelics Delix Therapeutics
From Benzinga
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
Tickers ATAI NVMDF
Tags Biotech Benzinga Novamind Inc/
From Benzinga
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
Tickers BRAXF FTRP MCURF NVMDF
Tags PHRRF $DOGE Markets
From Benzinga
'Psychedelics Without Hallucinations': Concept Get Closer To Human Trials With $70M Funding
Tags Benzinga Markets Delix Therapeutics
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.